A small proof-of-principle trial suggests MDMA-assisted therapy may be feasible for depression, though the open-label design and pre-treated sample warrant caution.

The FDA has approved Axsome's Auvelity (dextromethorphan/bupropion) as the first non-antipsychotic treatment for agitation associated with Alzheimer's disease, offering a new pharmacologic option for this indication.

Preclinical and early human data suggest minocycline may be effective for panic disorder, showing effects comparable to clonazepam.

A randomized trial published in the BMJ demonstrates that a five-day course of theta-burst transcranial magnetic stimulation significantly improves social communication and language in autistic children with intellectual disability, offering a non-pharmacologic treatment option.

The FDA has approved the first non-antipsychotic medication for treating agitation associated with Alzheimer's disease, offering a new prescribing option for this behavioral symptom.

MapLight Therapeutics has completed enrollment in two Phase 2 clinical trials evaluating its investigational compounds for schizophrenia and autism spectrum disorder.

The FDA has paused Newron's Phase 3 schizophrenia trial following a patient death, signaling a critical safety signal that may impact the development of this investigational antipsychotic.

A patient death has halted Newron's late-stage clinical trial for a schizophrenia treatment, representing a significant setback in the drug development pipeline for this indication.

This systematic review protocol aims to synthesize human neuroimaging data on dopaminergic dysregulation in opioid use disorder to identify mechanistic targets for novel pharmacotherapies beyond current mu-opioid receptor agonists.

Teva acquired Emalex for $700M to advance its experimental drug for Tourette syndrome, signaling continued investment in neurologic and psychiatric therapeutic pipelines.

A small trial suggests semaglutide reduces heavy drinking days in patients with alcohol use disorder and obesity, highlighting a potential repurposing opportunity for GLP-1 agonists in substance use treatment.

Qualitative study reveals that people who use drugs are willing to use higher dose naloxone for opioid overdoses but remain skeptical due to concerns about precipitated withdrawal and pharmaceutical marketing.

This case report suggests low-dose mirtazapine as a viable pharmacologic alternative to SSRIs for treating compulsive polydipsia in autistic patients, avoiding the risk of SSRI-induced hyponatremia.

This case report describes the use of patient-selected music as an adjunctive intervention to mitigate transient dissociative and ataxic side effects during intranasal esketamine treatment for treatment-resistant depression, potentially improving tolerability and adherence.

A clinical trial is recruiting to evaluate the efficacy and safety of the dual orexin receptor antagonist daridorexant for treating insomnia in patients with major depressive disorder.

This study analyzes intracranial neural activity in three treatment-resistant depression patients to characterize the network effects of combinatorial deep brain stimulation targets, providing mechanistic insights for optimizing surgical parameters.

This study characterizes the acute dose-dependent effects of the psychedelic 2C-B relative to MDMA and psilocybin in healthy volunteers, providing mechanistic insights into psychedelic pharmacology relevant to future psychiatric therapeutic development.

This study identifies the default mode network as a potential neuroimaging biomarker for predicting antidepressant response, offering insights into the neural mechanisms underlying treatment efficacy in depression.

This systematic review evaluates intracranial neural biomarkers to guide closed-loop neuromodulation therapies for treatment-resistant psychiatric disorders, highlighting the need to account for disorder-specific symptom time constants.